NDAC nominations
This article was originally published in The Tan Sheet
Executive Summary
Nominations for a non-voting industry representative to serve on the Nonprescription Drugs Advisory Committee must be received by FDA no later than Dec. 15, the agency announces in the Nov. 15 Federal Register. Industry organizations interested in participating in the member's selection should notify FDA by letter. The agency will compile a list of nominees by Dec. 15 and will forward the list to participating organizations. A candidate must be selected by participants within 60 days of receipt of the FDA letter. If no candidate is chosen, the FDA commissioner will select the non-voting member, FDA notes. Self-nominations are acceptable and organizations may submit multiple nominations...
You may also be interested in...
CHPA NDAC nomination
CHPA nominates George Goldstein, MD, to represent the industry on FDA's Nonprescription Drugs Advisory Committee, the organization states in a Nov. 28 letter to FDA. The Consumer Healthcare Products Association polled members to identify Goldstein as the "consensus candidate" for industry representative. Goldstein comes to the table with a resume that includes 14 years in private practice as a pediatrician and 15 years with Sterling Drug, according to CHPA. Goldstein served as Chief Medical Officer for Sterling's OTC division, Glenbrook Labs, as well as for the Rx division, Winthrop Labs. FDA announced in November that it was taking nominations for a non-voting industry representative to serve on the committee ("The Tan Sheet" Nov. 21, 2005, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.